Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced Dose of Pegfilgrastim in Breast Cancer
NCT05283616Phase 3Completed
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- May 2017
- Primary completion
- Oct 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of pegfilgrastim in neutropenia, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Started May 2017; status: completed.
02
Drugs
pegfilgrastim
03
Conditions
neutropenia
Beyond the preview
Go deeper on NCT05283616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05283616.